<DOC>
	<DOCNO>NCT02559869</DOCNO>
	<brief_summary>This multicenter , 18-month study , aim identify image biofluid biomarkers people ALS expand understand ALS pathology , treatment target , disease progression , anatomical difference different disease phenotype . This pilot project tailor produce image tool allow researcher conduct future ALS clinical trial efficiently may turn impact pace ALS drug discovery .</brief_summary>
	<brief_title>Imaging BioFluid Biomarkers Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>In trial , approximately 200 subject participate study 2 Northeast ALS Consortium ( NEALS ) center United States . Fifty ( 50 ) ALS participant age gender match 50 participant know neurological disorder ( healthy control ) . Of , twenty five ( 25 ) ALS participant age ( Â±5 year ) gender bind affinity ( TSPO ) match 25 healthy control . During enrollment period 200 participant screen 100 participant ultimately scan . There maximum allow time 45 day screen baseline visit ( 1st scan ) . All 100 subject undergo MRI scan clinical assessment Baseline Visit . Healthy control participants follow-up visit complete participation screen baseline visit . Only 50 subject sample undergo PET scanning . The ALS participant return follow-up MRI scan clinical assessment every three month follow-up PET scan every 6 month 12-month period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Inclusion Criteria Study subject meeting follow criterion allow enroll study : 1 . Male female , age 18 80 2 . Medically safe undergo MRI scan 3 . Able safely lie supine least 90 minute opinion Site Investigator 4 . Capable provide informed consent follow trial procedure 5 . Geographically accessible site ALS subject must also meet follow criterion : 1 . Sporadic familial ALS diagnose possible , laboratorysupported probable , probable , definite define modified El Escorial criterion 2 . ALS Cognitive Behavioral Screen score &gt; 10 cognitive scale and/or &gt; 32 behavioral scale Those ALS subject participate optional lumbar puncture portion study must also meet follow criterion : 1 . Subjects medically able undergo lumbar puncture ( LP ) determine investigator ( i.e. , bleed disorder , allergy local anesthetic , skin infection near LP site , evidence high intracranial pressure ) . For subject participate PET scan portion study , subject must also meet follow criterion : 1 . Medically safe undergo PET scan 2 . No prior radiation exposure exceed site 's current guideline 3 . No known allergy component tracer 4 . Baseline ECG value within normal range 5 . Subjects must meet main study entry criterion Exclusion Criteria Study subject meeting follow criterion screen evaluation exclude entry study : 1 . Any contraindication undergo MRI study 1 . History cardiac pacemaker pacemaker wire 2 . Metallic particle body 3 . Vascular clip head 4 . Prosthetic heart valves 5 . Claustrophobia 2 . Diagnosis Parkinson 's disease Alzheimer 's disease 3 . Diagnosis renal failure 4 . Have active chronic autoimmune disease ( hepatitis HIV ) , infection , take immunosuppressive medication steroid , cyclophosphamide , etc . 5 . Presence diaphragm pace system ( DPS ) 6 . The presence unstable psychiatric disease , cognitive impairment , dementia would impair ability subject provide inform consent , accord SI judgment 7 . Pregnant woman woman currently breastfeed 8 . Anything , opinion investigator , would place subject increase risk preclude subject 's full compliance completion study In addition , subject meeting follow criterion screen evaluation exclude entry PET portion study : 1 . Radiation exposure exceed site 's current guideline 2 . Low affinity TSPO binder determine Thr/Thr polymorphism TSPO gene ( rs6971 ) Screening Visit Women Childbearing Potential ( WOCBP ) For purpose study , woman child bear potential defined woman capable become pregnant , unless meet one follow criterion : 12months postmenopausal Posthysterectomy Surgically sterile</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Biofluid</keyword>
	<keyword>ALS</keyword>
	<keyword>MRI</keyword>
	<keyword>PET</keyword>
	<keyword>Imaging</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>TRACK ALS</keyword>
	<keyword>pathology</keyword>
</DOC>